Pdha1, also known as pyruvate dehydrogenase E1 component subunit alpha, is a key enzyme in the tricarboxylic acid cycle. It links glycolysis to the mitochondrial citric acid cycle by catalyzing the conversion of pyruvate to acetyl-CoA, thus playing a crucial role in energy metabolism [1-6].

In sepsis-induced acute kidney injury (SAKI), down-regulation of Sirtuin 3 (SIRT3) leads to PDHA1 hyperacetylation and inactivation, causing lactate overproduction [1]. In cholangiocarcinoma, succinylation of PDHA1 lysine 83 changes PDH enzyme activity, modulates metabolic flux, and promotes immune escape [2]. In colorectal cancer, RNF4-mediated degradation of PDHA1 promotes glycolytic metabolism, proliferation, and metastasis [3]. In cervical cancer, AP2α negatively regulates PDHA1 to promote aggressive features and aerobic glycolysis [4].

In conclusion, Pdha1 is essential for energy metabolism, connecting glycolysis to the citric acid cycle. Studies using various models, including those related to SAKI, cholangiocarcinoma, colorectal cancer, and cervical cancer, have revealed its significance in disease-related metabolic reprogramming and disease progression. Understanding Pdha1 provides insights into disease mechanisms and potential therapeutic targets in these disease areas.